DK620089A - Monoklonalt antistof til formindskelse af vaevsbeskadigelse paa et betaendt sted - Google Patents

Monoklonalt antistof til formindskelse af vaevsbeskadigelse paa et betaendt sted Download PDF

Info

Publication number
DK620089A
DK620089A DK620089A DK620089A DK620089A DK 620089 A DK620089 A DK 620089A DK 620089 A DK620089 A DK 620089A DK 620089 A DK620089 A DK 620089A DK 620089 A DK620089 A DK 620089A
Authority
DK
Denmark
Prior art keywords
monoclonal antibody
inhibit
reduce table
situation place
table damage
Prior art date
Application number
DK620089A
Other languages
English (en)
Other versions
DK620089D0 (da
Inventor
Robert F Todd Iii
Paul J Simpson
Benedict R Lucchesi
Stuart F Schlossman
James D Griffin
Original Assignee
Univ Michigan
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/061,336 external-priority patent/US4840793A/en
Application filed by Univ Michigan, Dana Farber Cancer Inst Inc filed Critical Univ Michigan
Publication of DK620089D0 publication Critical patent/DK620089D0/da
Publication of DK620089A publication Critical patent/DK620089A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DK620089A 1987-06-11 1989-12-08 Monoklonalt antistof til formindskelse af vaevsbeskadigelse paa et betaendt sted DK620089A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/061,336 US4840793A (en) 1987-06-11 1987-06-11 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US07/165,025 US4935234A (en) 1987-06-11 1988-03-07 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
PCT/US1988/001928 WO1988009672A1 (en) 1987-06-11 1988-06-03 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody

Publications (2)

Publication Number Publication Date
DK620089D0 DK620089D0 (da) 1989-12-08
DK620089A true DK620089A (da) 1990-02-07

Family

ID=26740960

Family Applications (1)

Application Number Title Priority Date Filing Date
DK620089A DK620089A (da) 1987-06-11 1989-12-08 Monoklonalt antistof til formindskelse af vaevsbeskadigelse paa et betaendt sted

Country Status (12)

Country Link
US (1) US4935234A (da)
EP (1) EP0371036B1 (da)
JP (1) JPH02503796A (da)
CN (1) CN1034055C (da)
AT (1) ATE126703T1 (da)
AU (1) AU621304B2 (da)
BR (1) BR8807559A (da)
CA (1) CA1317880C (da)
DE (1) DE3854351T2 (da)
DK (1) DK620089A (da)
NO (1) NO894946L (da)
WO (1) WO1988009672A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019648A (en) * 1987-07-06 1991-05-28 Dana-Farber Cancer Institute Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
ZA903223B (en) * 1989-04-28 1991-02-27 Baylor College Medicine Dissemination of hiv-1 infected cells
WO1992003473A1 (en) * 1990-08-27 1992-03-05 Cetus Corporation Cd18 peptide medicaments for the treatment of disease
WO1992006697A1 (en) * 1990-10-23 1992-04-30 Repligen Corporation Anti-inflammatory composition
JPH06505969A (ja) * 1991-01-11 1994-07-07 レプリジェン　コーポレーション 炎症性損傷防止方法
US5322699A (en) * 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
WO1993024614A1 (en) * 1992-05-22 1993-12-09 The Research And Development Institute, Inc. Antibodies with specificity for multiple adhesion molecules
EP0670734A4 (en) * 1992-10-09 1998-01-14 Blood Res Center SUB-POPULATION OF Mac-1 MOLECULES (CD11B / CD 18) THAT INDUCE NEUTROPHILIC ADHESION TO ICAM-1 AND FIBRINOGEN.
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5656441A (en) * 1994-04-19 1997-08-12 Trustees Of Boston University Methods for determining cellular adhesion
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
AU4000500A (en) * 1999-02-17 2000-09-04 Genentech Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
US6663863B2 (en) 2000-03-17 2003-12-16 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2003217747A1 (en) * 2002-02-26 2003-09-09 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2007530586A (ja) 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
EP1819827B1 (en) * 2004-12-08 2010-08-11 Cedars-Sinai Medical Center Methods for diagnosis of crohn's disease
CN102793972A (zh) 2004-12-27 2012-11-28 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405107B1 (en) 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2021236977A1 (en) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody

Also Published As

Publication number Publication date
EP0371036B1 (en) 1995-08-23
CN1033242A (zh) 1989-06-07
DE3854351T2 (de) 1996-03-21
JPH02503796A (ja) 1990-11-08
NO894946L (no) 1990-01-23
DK620089D0 (da) 1989-12-08
WO1988009672A1 (en) 1988-12-15
AU621304B2 (en) 1992-03-12
CA1317880C (en) 1993-05-18
EP0371036A4 (en) 1990-06-27
NO894946D0 (no) 1989-12-08
BR8807559A (pt) 1990-05-22
CN1034055C (zh) 1997-02-19
ATE126703T1 (de) 1995-09-15
AU1946388A (en) 1989-01-04
DE3854351D1 (de) 1995-09-28
EP0371036A1 (en) 1990-06-06
US4935234A (en) 1990-06-19

Similar Documents

Publication Publication Date Title
DK620089A (da) Monoklonalt antistof til formindskelse af vaevsbeskadigelse paa et betaendt sted
DK641889A (da) Anvendelse af en blodpladeaktiveringsfaktorantagonist i kombination med monoklonale eller polyklonale antistoffer i et farmaceutisk praeparat til behandling af endotoksisk chok hos pattedyr
NL970045I2 (nl) Desulfatohirudinen, werkwijze voor hun bereiding en farmaceutische middelen.
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
ATE165511T1 (de) Behandlung von organtransplantatsabstossung
DE69109583D1 (de) Verfahren zur Behandlung von entzündlichen Darmerkrankungen.
DK0801572T3 (da) Sammensætning til inhibering af intimal hyperplasi ved anvendelse af PDGF-antagonister og heparin
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
DE69027220D1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
BE837705A (nl) Werkwijze voor het verharden van proteinhoudende lagen
Horovitz et al. Immunologic observations on homografts: II. The canine kidney
DK531089D0 (da) Bicycliske imidazolforbindelser til anvendelse ved behandling af hyperaldosteronisme
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
Mayrhofer et al. IgA‐containing plasma cells in the lamina propria of the gut: failure of a thoracic duct fistula to deplete the numbers in rat small intestine
Ueda et al. Experimental gold nephropathy in guinea pigs: detection of autoantibodies to renal tubular antigens
NL7806442A (nl) Werkwijze voor het minimaal maken van verdampingsver- liezen van opgeslagen koolwaterstoffen alsmede samen- stelling voor toepassing in deze wijze.
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE55059T1 (de) Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen.
Williams et al. Comparative study on the procoagulant from the venom of Australian brown snakes (Elapidae; Pseudonaja spp.)
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
UA26438A (uk) СПОСІБ ОТРИМАHHЯ СУЛЬФОHІЛФЕHІЛ- БЕttА-D-ТІОКСИЛОЗИДІВ
DK320081A (da) Fremgangsmaade til fremstilling af thiazolyl-2-oxamidsyrederivater
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
SUZUKI et al. Localization of glomerular fibronectin in human and experimental glomerulonephritis
Loewi Immune Complex Arthritis-In Man and Experimental Animals

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment